World Health Organization et al., 2026-11-19: WHO's electronic essential medicines list gives mebendazole's listing history from 1977 onward and states that patents have expired in most jurisdictions. It dates the drug's entry onto the WHO list and confirms the patent status independently of the US Orange Book.
EML status history First added in 1977 (TRS 615) Changed in 1979 (TRS 641) Changed in 1982 (TRS 685) Changed in 1987 (TRS 770) Changed in 1995 (TRS 867) Changed in 2007 (TRS 950) Changed in 2011 (TRS 965)
p. 1
World Health Organization et al., 2026-11-19: WHO's electronic essential medicines list gives mebendazole's listing history from 1977 onward and states that patents have expired in most jurisdictions. It dates the drug's entry onto the WHO list and confirms the patent status independently of the US Orange Book. Record-field transcription of a database entry, hence MEDIUM. The page also states: 'Patent information – Patents have expired in most jurisdictions', formulation 'Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)', ATC P02CA01, list type Core, and 'The recommendation is for this specific medicine'. Access date 2026-11-19 (page undated). The EML history is the WHO's own record; the patent sentence is a summary statement without a jurisdiction-by-jurisdiction table, so it corroborates rather than replaces the US patent expiry evidence at MBA-05. access date, page undated.
